SCHEMBL5185353

SCHEMBL5185353

COC(=O)C1c2ccccc2C(NC(=O)OCc2ccccc2)CN1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPB1 P15086 1/20 0.49
ALDH1A1 P00352 3/20 0.44
GAA P10253 1/20 0.44
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
CTSK P43235 1/20 0.44
TSHR P16473 3/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP1A2 P05177 1/20 0.43
POLB P06746 1/20 0.43
CYP2D6 P10635 1/20 0.43
NAAA Q02083 1/20 0.43
CA1 P00915 3/20 0.43
CA2 P00918 3/20 0.43
ACHE P22303 3/20 0.43
CASP1 P29466 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
FKBP1A P62942 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5185346 1.00 CPB1 (0.49) CPB1ALDH1A1GAACTSLCTSB
SCHEMBL5185361 1.00 CPB1 (0.49) CPB1ALDH1A1GAACTSLCTSB
SCHEMBL5187929 0.91 CPB1 (0.50) CPB1ALDH1A1GAACTSLCTSB
SCHEMBL5187939 0.91 CPB1 (0.50) CPB1ALDH1A1GAACTSLCTSB
SCHEMBL5187949 0.91 CPB1 (0.50) CPB1ALDH1A1GAACTSLCTSB
SCHEMBL5257429 0.90 ALDH1A1 (0.50) CPB1ALDH1A1GAACTSLCTSB
SCHEMBL5187275 0.84 GPR183 (0.39) CPB1ALDH1A1TSHRCYP2C9CYP2C19
SCHEMBL5256547 0.81 ALDH1A1 (0.48) CPB1ALDH1A1GAACTSLCTSB
SCHEMBL5185551 0.77 CPB1 (0.51) CPB1ALDH1A1GAACTSLTSHR
SCHEMBL5185537 0.77 CPB1 (0.51) CPB1ALDH1A1GAACTSLTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288549-B2 Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents AVENTIS PHARMA S.A. (FR) 2007-10-30 US disclosed
US-20050245505-A1 Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents ENTASIS THERAPEUTICS LIMITED (GB) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245505-A1 Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents FDPS, MRPL21, DHPS CPB1 1734/4885ALDH1A1 1565/4885GAA 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.